Skip to content
Screener

Dianthus Therapeutics DNTH Q1 2025 earnings

Reported May 12, 2025 · Before market open

Revenue$1.2MBeat by $356.1K
EPS-$0.82Beat by $0.04
Revenue estimate$806.9K
EPS estimate-$0.86

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$443.9K
EPS estimate-$0.94

Financials

Q1 2025

Income statement

See full
Revenue$1.2M+33.1%
Operating income-$33.2M-85.9%
Net income-$29.5M-115%
EPS (diluted)-$0.82-51.9%

Balance sheet

See full
Cash & equivalents$10.1M-96.9%
Total debt$1.4M+181%
Total equity$328.6M-11.8%
Total assets$348.6M-8.9%

Cash flow

See full
Operating cash flow-$27.6M-84.9%
CapEx$24.0K-25.0%
Free cash flow-$27.7M-84.7%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$582.75M-24.3%
Enterprise value$574.03M+30.2%
P/S89.3×—

Profitability

See full
Operating margin-1,796.4%—
Net margin-1,544%—
FCF margin-1,394.3%—

Returns & leverage

See full
Return on equity-28.7%—
Debt / equity0×0.0×
Current ratio16×-26.5×

Segments

By product

See full
License$1.2M+33.1%

FAQ

When did Dianthus Therapeutics report Q1 2025 earnings?
Dianthus Therapeutics (DNTH) reported Q1 2025 earnings on May 12, 2025 before market open.
What were Dianthus Therapeutics's Q1 2025 revenue and EPS?
Dianthus Therapeutics reported revenue of $1.2M and eps of $-0.82 for Q1 2025.
Did Dianthus Therapeutics beat estimates in Q1 2025?
Revenue beat the consensus estimate of $806.9K by $356.1K. EPS beat the consensus estimate of $-0.86 by $0.04.
How did Dianthus Therapeutics's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 33.1% from $874.0K a year earlier and eps declined 51.9% from $-0.54.
Where can I find Dianthus Therapeutics's Q1 2025 SEC filings?
You can read the 8-K earnings release (0000950170-25-069195) and the 10-Q periodic report (0000950170-25-069226) directly on SEC EDGAR. The filing index links above go to sec.gov.